Issue 2/2015

Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia patients – worldwide battlefield (167 — 171)

P. DVORAK, D. LYSAK, S. VOKURKA

DOI: 10.4149/neo_2015_021

Sorafenib-irinotecan sequential therapy augmented the anti-tumor efficacy of monotherapy in hepatocellular carcinoma cells HepG2 (172 — 179)

Z. WANG, Z. ZHAO, T. WU, L. SONG, Y. ZHANG

DOI: 10.4149/neo_2015_022

The endoplasmic reticulum stress response is associated with insulin resistance-mediated drug resistance in HepG2 cells (180 — 190)

L. LI, G. LI, H. WEI, J. SUN, J. CHEN, B. XIE, B. WANG, J. GU, C. LI, B. TIAN, F. WANG

DOI: 10.4149/neo_2015_023

MicroRNA 363 mediated positive regulation of c-myc translation affect prostate cancer development and progress (191 — 198)

Y. CHEN, X. LU, B. WU, Y. SU, J. LI, H. WANG

DOI: 10.4149/neo_2015_024

Autophagy facilitates multidrug resistance development through inhibition of apoptosis in breast cancer cells (199 — 208)

W. L. SUN, D. LAN, T. Q. GAN, Z. W. CAI

DOI: 10.4149/neo_2015_025

Inhibitory effects of indirubin derivative PHII-7 on invasion and migration in metastatic cancer (209 — 229)

X. GAO, Y. ZHOU, K. X. WU, Y. H. DING, D. M. FAN, M. YANG, Y. Z. ZHANG, Y. J. ZHANG, D. S. XIONG

DOI: 10.4149/neo_2015_026

Autophagy inhibitor sensitizes MCF-7 breast cancer cells to novel cyclic tetrapeptide CTS203-induced caspase-9-dependent apoptotic cell death (220 — 229)

S. WANG, X. LI, Q. WANG, Z. XIU

DOI: 10.4149/neo_2015_027

Genome-wide pathway analysis in glioma (230 — 238)

Y. H. LEE, G. G. SONG

DOI: 10.4149/neo_2015_028

Pre- and post-operative evaluation: percentages of circulating myeloid-derived suppressor cells in rectal cancer patients (239 — 249)

L. YUAN, B. XU, H. FAN, P. YUAN, P. ZHAO, Z. SUO

DOI: 10.4149/neo_2015_029

Clinical significance of microRNA-24 expression in esophageal squamous cell carcinoma (250 — 258)

W. DONG, B. LI, Z. WANG, Z. ZHANG, J. WANG

DOI: 10.4149/neo_2015_030

Predictive factors for the presence of tumor cells in bone marrow and peripheral blood in breast cancer patients (259 — 268)

M. CABINAKOVA, V. MIKULOVA, K. MALICKOVA, D. VRANA, D. PAVLISTA, L. PETRUZELKA, T. ZIMA, P. TESAROVA

DOI: 10.4149/neo_2015_031

MR-mammography – impact on disease extent determination and surgical treatment of invasive ductal and lobular breast cancers (269 — 277)

V. LEHOTSKA, K. RAUOVA, L. VANOVCANOVA 

DOI: 10.4149/neo_2015_032

Clinical significance of ERG rearrangement subtype and its association with increased p53 expression in Japanese and German prostate cancer (278 — 287)

J. NISHIJIMA, T. HARA, K. IKEMOTO, A. OGA, K. KOBAYASHI, Y. KAWAI, H. MATSUMOTO, K. NAGAO, K. SASAKI, V. GKOLEIZAKIS, J. FICHTNER, H. MATSUYAMA

DOI: 10.4149/neo_2015_033

Decreased bone mineral density and alteration in biochemical bone metabolism markers in children affected by bone tumors after completion of therapy (288 — 294)

J. AMBROSZKIEWICZ, J. GAJEWSKA, E. ROGOWSKA, K. SZAMOTULSKA, M. CHELCHOWSKA, G. ROWICKA, M. RYCHLOWSKA-PRUSZYNSKA

DOI: 10.4149/neo_2015_034

Comparison of 18F-FDG PET/CT and MDCT for staging/restaging of non-small cell lung cancer (295 — 301)

D. SOBIC-SARANOVIC, I. PETRUSIC, V. ARTIKO, S. PAVLOVIC, D. SUBOTIC, D. SARANOVIC, L. NAGORNI-OBRADOVIC, N. PETROVIC, M. TODOROVIC-TIRNANIC, S. ODALOVIC, I. GROZDIC-MILOJEVIC, M. STOILJKOVIC, V. OBRADOVIC

DOI: 10.4149/neo_2015_035

Gefitinib maintenance therapy in Chinese advanced-stage lung adenocarcinoma patients with EGFR mutations treated with prior chemotherapy (302 — 307)

K. C. CAI, D. G. LIU, Y. Y. WANG, H. WU, Z. Y. HUANG, R. J. CAI, H. F. WANG, G. XIONG, Z. L. ZHANG

DOI: 10.4149/neo_2015_036

Impact of risk factors on prevalence of anal HPV infection in women with simultaneous cervical lesion (308 — 314)

J. SLAMA, B. SEHNAL, L. DUSEK, T. ZIMA, D. CIBULA

DOI: 10.4149/neo_2015_037

Assessing the interactions between the associations of common genetic variants on 2q35 and 16q12 with breast cancer risk (315 — 325)

Y. L. FAN, Z. J. GUO, P. ZHU, X. J. YANG, X. D. YANG, B. YU, L. H. LI

DOI: 10.4149/neo_2015_038

Daily image-guidance in prostate cancer radiotherapy – implications for treatment margins (326 — 331)

G. GLOWACKI, W. MAJEWSKI, P. WOJCIESZEK, A. TUKIENDORF, D. BODUSZ, G. WOZNIAK, L. MISZCZYK

DOI: 10.4149/neo_2015_039

Elevated Farnesoid X Receptor (FXR) and Retinoid X Receptors (RXRs) expression is associated with less tumor aggressiveness and favourable prognosis in patients with pancreatic adenocarcinoma (332 — 341)

C. GIAGINIS, I. KOUTSOUNAS, P. ALEXANDROU, A. ZIZI-SERBETZOGLOU, E. PATSOURIS, G. KOURAKLIS, S. THEOCHARIS

DOI: 10.4149/neo_2015_040